Shenzhen Kangtai Biological Products Co., Ltd. (SHE:300601)

Market Cap	14.17B -28.4%
Revenue (ttm)	2.66B -6.5%
Net Income	81.24M -52.2%
EPS	0.07 -53.8%
Shares Out	1.12B
PE Ratio	182.70
Forward PE	81.14
Dividend	0.04 (0.28%)
Ex-Dividend Date	Jun 11, 2026

Volume	19,793,311
Open	12.68
Previous Close	12.78
Day's Range	12.62 - 13.15
52-Week Range	10.70 - 21.12
Beta	0.62
Analysts	Buy
Price Target	16.44 (+29.55%)
Earnings Date	Aug 22, 2026

About SHE:300601

Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus acellular pertussis and haemophilus influenzae type B combined vaccines; diphtheria, tetanus, and acellular pertussis combined vaccine, adsorbed; rabies v...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 1,957
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300601

Financial Performance

In 2025, SHE:300601's revenue was 2.67 billion, an increase of 0.81% compared to the previous year's 2.65 billion. Earnings were 70.33 million, a decrease of -65.12%.

Analyst Summary

According to 4 analysts, the average rating for 300601 stock is "Buy." The 12-month stock price target is ¥16.44, which is an increase of 29.55% from the latest price.

Price Target

¥16.44

(29.55% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 14, 2026

Data Sources Report a data error